



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/229260/2012

## European Medicines Agency decision P/0080/2012

of 27 April 2012

on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir (Victrelis), (EMA-000583-PIP01-09-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0080/2012

of 27 April 2012

on the acceptance of a modification of an agreed paediatric investigation plan for boceprevir (Victrelis), (EMA-000583-PIP01-09-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the European Medicines Agency's decision P/97/2010 issued on 4 June 2010, the decision P/154/2010 issued on 27 August 2010, the decision P/88/2011 issued on 8 April 2011, and the decision P/283/2011 issued on 29 November 2011,

Having regard to the application submitted by Merck Sharp & Dohme Ltd on 16 December 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 9 March 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for boceprevir (Victrelis), granules, hard capsules, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to Merck Sharp & Dohme Ltd, Hertford Road, EN11 9BU – Hoddesdon, United Kingdom.

Done at London, 27 April 2012

For the European Medicines Agency  
Guido Rasi  
Executive Director  
(Signature on file)



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/122475/2012

## Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000583-PIP01-09-M04

### **Scope of the application**

**Active substance(s):**

Boceprevir

**Invented name:**

Victrelis

**Condition(s):**

Treatment of Chronic Hepatitis C

**Authorised indication(s):**

See Annex II

**Pharmaceutical form(s):**

Granules

Hard capsules

**Route(s) of administration:**

Oral use

**Name/corporate name of the PIP applicant:**

Merck Sharp & Dohme Ltd

**Information about the authorised medicinal product:**

See Annex II



## **Basis for opinion**

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme Ltd submitted to the European Medicines Agency on 16 December 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/97/2010 issued on 4 June 2010, the decision P/154/2010 issued on 27 August 2010, the decision P/88/2011 issued on 8 April 2011, and the decision P/283/2011 issued on 29 November 2011.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 January 2012.

## **Scope of the modification**

Some measures and timelines of the Paediatric Investigation Plan have been modified.

## **Opinion**

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 9 March 2012

On behalf of the Paediatric Committee  
Dr Daniel Brasseur, Chairman  
(Signature on file)

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan**

# 1. Waiver

## 1.1. Condition: Treatment of Chronic Hepatitis C

The waiver applies to:

- Paediatric population from birth to less than 3 years of age;
- for hard capsules, granules, oral use;
- on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

# 2. Paediatric Investigation Plan

## 2.1. Condition: Treatment of Chronic Hepatitis C

### 2.1.1. Indication(s) targeted by the PIP

Treatment of children and adolescents from 3 years to less than 18 years of age with genotype 1 chronic HCV infection and without liver decompensation.

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 3 to less than 18 years of age.

### 2.1.3. Pharmaceutical form(s)

Hard capsules, granules, oral use

### 2.1.4. Studies

| Area         | Number of studies | Description                                                                                                                                                                                                                                                                                                                                     |
|--------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Quality      | 1                 | Study 1: Development of the granule formulation, including palatability testing, formulation selection and manufacture, bioavailability testing, and formulation development scale-up.                                                                                                                                                          |
| Non-clinical | 3                 | Study 2: One-month thyroid hormone evaluation study of boceprevir in juvenile rats.<br>Study 3: Testicular toxicity and toxicokinetic study of oral (gavage) boceprevir in male neonatal rats.<br>Study 4: Thyroxine Clearance Study of Boceprevir in Juvenile Rats.<br>Study 5: Repeat Thyroxin Clearance Study of Boceprevir in Juvenile Rats |
| Clinical     | 2                 | Study 6: PK Assessment Boceprevir in Paediatric Subjects With Chronic Hepatitis C Genotype 1.<br>Study 7: Efficacy and Safety of Boceprevir in Combination with Peginterferon                                                                                                                                                                   |

| Area | Number of studies | Description                                                                        |
|------|-------------------|------------------------------------------------------------------------------------|
|      |                   | alfa-2b Plus Ribavirin in Paediatric Subjects With Chronic Hepatitis C Genotype 1. |

### 3. Follow-up, completion and deferral of PIP

|                                                                                           |                  |
|-------------------------------------------------------------------------------------------|------------------|
| Concerns on potential long term safety and efficacy issues in relation to paediatric use: | Yes.             |
| Date of completion of the paediatric investigation plan:                                  | By January 2016. |
| Deferral for one or more studies contained in the paediatric investigation plan:          | Yes.             |

## **Annex II**

### **Information about the authorised medicinal product**

**Condition(s) and authorised indication(s):**

## 1. Treatment of chronic hepatitis C

Authorised indications:

Treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

| <b>EU Number</b> | <b>Investigational name</b> | <b>Strength</b> | <b>Pharmaceutical form</b> | <b>Route of administration</b> | <b>Packaging</b>  | <b>Content (concentration)</b> | <b>Package size</b> |
|------------------|-----------------------------|-----------------|----------------------------|--------------------------------|-------------------|--------------------------------|---------------------|
| EU/1/11/704/001  | Victrelis                   | 200 mg          | Capsule, hard              | Oral use                       | Blister (PVC/alu) |                                | 336 (4 packs of 84) |